Abstract: The present invention discloses therapeutic compositions comprising herbal extracts and essential oils for smoking and vaporization useful in the treatment of various symptoms and diseases. More particularly the invention relates to compositions comprising herbal extracts and essential oils capable of providing therapeutic benefits, which helps to improve conditions like cough, cold, pain, energy, relaxation, calmness, digestion, immune system disorders and neurological disorders etc. The invention further relates to methods for treating the same using the compositions of the invention. The invention also discloses method of formulating a blend of herbal CO2 extracts and essential oils without the use of any type of synthetic carriers or residual solvent or synthetic chemicals, thus improving quality, safety and efficacy.

Abstract: Disclosed is a topical skin composition, and methods for its use, that includes Arctium lappa root extract, Epilobium angustifolium extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract.

Abstract: An edible oral film strip dosage form containing an unpalatable basic active pharmaceutical ingredient and an ion exchange resin as a primary taste masking agent, along with an optional acidic agent and further optionally containing one or more secondary taste masking agents is provided. The edible oral film strip dosage matrix is formed from at least one water soluble or miscible polymer(s). The optional secondary taste masking ingredients include one or more of flavoring agent(s), sweetener(s), cooling sensation agent(s), and taste receptor blocker(s). Methods for preparing the inventive edible oral film strip dosage forms are disclosed, as well as their method of administration.

Abstract: This invention relates to a herbal composition and process for preparing a detoxifying herbal extract using the stem bark of the woody liana, Dalbergia horrida for treatment of snake bite, specifically Cobra (Naja naja) and Russell's viper (Daboia russelli) in mammalians. The herbal composition can also be used to treat venomous bites of krait, bugarus caeruleus, Saw scaled viper, Echis carinaturs, Monocelled cobra, Naja kaouthia and King cobra, Oohiophagus hannah. An extract (Dalbergia horrida) can be performed utilizing an ethanol solvent. Further, the extract can be performed utilizing a methanol solvent (an alcoholic solvent) separately. The ethanol extraction and methanol extraction of the herb can be performed using a common plant extraction approach (CPEA). The concentrated ethanol and methanol solvents can be pooled together to obtain a novel detoxifying herbal extract for treatment of snake bite.

Abstract: The invention relates to compositions and to the methods of administration thereof. More specifically, it relates to an optimised method for the administration of active agents to non-human mammals by means of topical application of pre-determined doses.

Abstract: The present invention provides a therapeutically effective composition and method of treatment of neuropathic pain utilizing extracts of Monarda, for example, Monarda fistulosa and related species, used alone or in a composition with a pharmaceutically acceptable carrier in a suitable dosage form.

Abstract: This invention relates to methods and compositions for providing improved insulin-sensitivity and/or enhanced insulin-like action, which leads to improved glucose uptake and utilization. This invention also relates to methods and compositions for lowering LDL, lowering triglycerides, increasing HDL, and lowering high blood pressure in a subject. The methods comprise administering to a subject an effective amount of a water extract of cinnamon and an effective amount of a water extract of Radix Astragali.

Abstract: The present disclosure relates to a pharmaceutical composition for preventing and treating senile dementia and preparation method thereof. The active ingredients of the pharmaceutical composition are prepared from raw medicinal materials comprising 20-50 parts by weight of Epimedii Folium and 15-55 parts by weight of Poria; or from raw medicinal materials comprising 20-50 parts by weight of Epimedii Folium, 15-55 parts by weight of Poria and 10-55 parts by weight of Acanthopanax, or from raw medicinal materials 20-50 parts by weight of Epimedii Folium, 15-50 parts by weight of Poria, 15-50 parts by weight of Acanthopanax and 6-15 parts by weight of Anemarrhenae Rhizoma.

Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.

Abstract: The present invention provides pharmacological compounds including a peptide epoxy ketone protease inhibitor conjugated to a binding moiety that directs the peptide epoxy ketone protease inhibitor to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and a peptide epoxy ketone protease inhibitor. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the peptide epoxy ketone protease inhibitor.

Abstract: In various embodiments, the present invention relates to a topical pharmaceutical composition for treating a skin condition, comprising a combination of agents, wherein the combination includes: a) one or more antimicrobial compounds; b) one or more trace elements; c) one or more tissue reconstruction elements; and d) one or more analgesics, and a pharmaceutically-acceptable carrier. In certain embodiments, the invention relates to a topical pharmaceutical composition comprising silver sulfadiazine, zinc oxide, lidocaine, bacitracin, neomycin (e.g., neomycin sulfate), polymixin B (e.g., polymixin B sulfate), vitamin E and Coenzyme Q10. In other embodiments, the invention relates to a method of treating a skin condition in a subject in need thereof, comprising administering to the subject a therapeutically-effective amount of topical pharmaceutical composition of the invention.

Abstract: A multifunctional polyethylene glycol-based hydrogel that includes a multi-arm polyethylene glycol cross-linking unit covalently bound to at least four multi-arm polyethylene glycol nanocarrier units, wherein each nanocarrier unit includes an agent coupled to the nanocarrier unit and each agent is selected from pH-lowering agents, bioadhesion agents, microbicidal-spermicidal agents, and agents that inhibit free and cell-associated HIV binding, provided that each nanocarrier unit comprises a different agent.

Abstract: The present disclosure provides for methods providing a pre/probiotic agent to a subject. Human Intelectin 1 (hIntL-1) has been shown to bind selectively to glycan components on bacteria, thereby promoting and protecting the microbiome.

Abstract: The present invention includes compositions and methods that take advantage of MFG-E8's role as a homeostatic regulator of osteoclasts for treating a bone disorder or regulating osteoclast activation. In one aspect, the invention includes a composition comprising an effective amount of milk fat globule-EGF factor 8 (MFG-E8) formulated for local administration and a pharmaceutically acceptable carrier or adjuvant. In another aspect, a method is included for regulating osteoclast activation and inhibiting bone loss at a target site comprising locally administering an effective amount of milk fat globule-EGF factor 8 (MFG-E8) to the target site.

Abstract: The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.

Abstract: A nutritional composition for a subject, comprising prolactin identical or similar or analogous to prolactin found in a natural food source, and at least one protective layer, wherein release of said prolactin from the composition in said subject is the result of an environmental event.

Abstract: The present invention provides pharmaceutical formulations for sustained release when administered at cold temperatures, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs.

Abstract: A method for treating ocular-disorders which, involve angiogenesis or neovascularization as part of their pathologic process. These types of retinal disorders can be categorized as (a) retinal vascular disorders (such as diabetic retinopathy, retinal vein occlusions and retinopathy of prematurity), (b) subretinal neovascular disorders (such as neovascular age-related macular degeneration, ocular histoplasmosis, pathologic myopia) (c) intraocular tumors (such as ocular melanoma, ocular lymphoma and retino-blastoma). The treatment for these ocular disorder involves the administration of an effective amount of human chorionic gonadotropin (hCG) antagonists, luteinizing hormone (LH) antagonists or hCG/LH receptor antagonists, optionally in combination with at least one additional bioactive agent.

Abstract: A method for the treatment of diabetes mellitus type 2 comprising administering (d) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, (e) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (f) metformin or/and a pharmaceutically acceptable salt thereof, to a subject in need thereof.

Abstract: Methods of treating obesity, metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes using a pentapeptide, LVKGRamide, derived from the C-terminus of Glucagon-Like Peptide 1 (GLP-1).

Abstract: The invention relates to the field of biotechnology and medicine, and specifically to insulin-containing injectable formulations used, in particular, for treating diabetes mellitus. The present formulation comprises insulin and a pharmacologically acceptable polymer having a hydrodynamic diameter of more than 4.5+/?0.5 nanometers. As said polymer, at least one polymer having a molecular weight of 20-70 kDa may be optimally used, and is selected from a group including: dextran, polyethylene glycol and albumin. As regards insulin formulations used, it is possible to use human recombinant insulin and genetically engineered analogs thereof used in the commercial formulations. Experiments have shown that using the aforementioned polymers provides insulin formulations with a prolonged effect without the use of chemical or genetic methods of modifying insulin molecules. The method of long acting formulations preparing is not dependent on biotherapeutics and thus it can be used over range of therapeutic proteins.

Abstract: A composition, in the form of an aqueous solution, including an insulin in hexameric form and at least one substituted citrate of formula I: in which: R1, R2, R3, identical or different, represent OH or AA, at least one of the R1, R2, R3 is an AA radical, AA is a radical resulting from a natural or synthetic aromatic amino acid comprising at least one phenyl group or indole group, substituted or not substituted, said AA radical having at least one free carboxylic acid function, and the carboxylic acid functions are in the form of a salt of an alkali metal selected from Na+ and K+.

Abstract: The present invention generally relates to methods, compositions and materials for treatment of and promotion of neurological functional recovery from neurological conditions including central nervous system injuries and/or diseases.

Abstract: Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (BPD).

Abstract: The present invention provides methods and compositions for the treatment of cardiovascular disorders comprising: a therapeutically effective amount of thioredoxin-1 or a thioredoxin-1 derivative in a pharmaceutical carrier to ameliorate one or more symptom of a cardiovascular disorder.

Abstract: The invention is directed to methods for preventing and/or treating nasal polyps. The invention is further directed to methods for preventing and/or treating rhinosinusitus. The invention is further directed to reducing inflammation of the paranasal sinuses.

Abstract: Methods and compositions for the treatment of mycobacteria infections, particularly antibiotic resistant strains. Of particular use in treating tuberculosis infections, including dormant or difficult to treat forms.

Abstract: Wound debridement compositions containing the proteolytic enzyme Seaprose and use of such compositions in wound treatment for the enzymatic debridement of wounds.

Abstract: Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.

Abstract: The present invention provides a methods and compositions for treating a patient having a skin condition characterized by vascular hyper-reactivity, such as chronic or episodic flushing or blushing, and/or rosacea. The method comprises applying a topical composition to affected areas of the patient's skin. The topical composition comprises an effective amount of a botulinum neurotoxin for decreasing vasodilation in cutaneous microvasculature, and a carrier for effectively transporting the botulinum toxin to the cutaneous microvasculature. The invention thereby provides a safe, effective, comfortable, and/or convenient manner of treating vascular hyper-reactivity in skin.

Abstract: Methods for treating urinary incontinence associated with neurogenic detrusor overactivity (NDO) and for reducing need for or frequency of clean intermittent catherization (CIC) by injecting a clostridial derivative to the bladder of a patient are disclosed.

Abstract: A composition comprising as components a polypeptide IMPI? (including wild type) and/or a polypeptide IMPI?-fusion and at least one antibiotic compound, in particular an aminoglycoside antibiotic, and/or at least one bactericidal compound, wherein the polypeptides, the at least one antibiotic and the at least one bactericidal compound is present in the composition in concentrations which exhibit in combination a synergistic effect against resistant bacteria.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.

Abstract: Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition, wherein a lower dose is given in the second administration than in the first administration, and wherein the second administration may be unadjuvanted.

Abstract: The present disclosure provides temperature sensitive essential nucleic acid molecules from a psychrophilic bacterium, proteins encoded by the nucleic acid molecules, as well as recombinant cells into which have been introduced such nucleic acid molecules. The disclosed recombinant cells containing one or more essential nucleic acid molecules from a psychrophilic bacterium are thereby made temperature sensitive, and can be administered to a mammal to induce an immune response in the mammal.

Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological compositions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections be the administration of an effective amount of compositions.

Abstract: The disclosure relates to immunogenic and vaccine compositions comprising Streptococcus exotoxins and/or bacterial thermolysins from M4 protease family. Also provided are kits, methods and uses of said compositions for treating or preventing laminitis in a hooved animal.

Abstract: The present invention provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the following genes: multigene-family 360 genes 9L, 10L, 11L, 12L, 13L and 14L; and multigene-family 505 genes 1R, 2R, 3R and 4R. The invention further provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the DP148R gene. The present invention also provides a vaccine comprising such an attenuated virus and its use to prevent ASF. Further, the invention relates to intranasal administration of an attenuated ASF virus.

Abstract: The present invention generally relates to the field of plant molecular biology and biotechnology as it applies to the production of plant-derived vaccines. More particularly, the present invention pertains to recombinant DNA molecules encoding a chimeric tetravalent dengue virus antigen, and vectors, transgenic plastids, transgenic plant cells, transgenic plants and transgenic parts of such plants comprising said recombinant DNA molecules as well as useful for preparing genetically transformed plant and plant cells. The invention includes plant optimized genes that encode chimeric tetravalent dengue virus antigen.

Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.

Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.

Abstract: The present invention concerns methods and means for identifying, producing, and engineering neutralizing molecules against influenza A viruses, and to the neutralizing molecules produced. In particular, the invention concerns neutralizing molecules against various influenza A virus subtypes, including neutralizing antibodies against H5 and/or H3 and/or H1, such as, for example all of H1, H3, and H5 subtypes, and methods and means for making such molecules.

Abstract: The present invention provides a pharmaceutical composition for inducing immune response in a subject, comprising: (a) an antigen with a concentration ranging from 1 ?g/ml to 100 ?g/ml; (b) CpG oligonucleotides having a sequence of 5?-tcgacgttcgtcgttcgtcgttc-3?, with a concentration ranging from 25 ?g/ml to 500 ?g/ml, and (c) an aluminium adjuvant with a concentration ranging from 25 ?g/ml to 500 ?g/ml. Such pharmaceutical composition can induce or boost immune response against antigen in the subject.

Abstract: Provided are methods and compositions that can he used to treat subjects having a viral infection by provoking an immune response using newly discovered antigens that are non-naturally occurring variations on viral glycoproteins. For example, provided are viral glycoproteins or a fragments thereof, or, DNA constructs encoding for such viral glycoproteins or fragments thereof, wherein the glycoprotein or fragment comprises a glycosylation sequon that includes a non-templated aspartic acid residue.

Abstract: A RNA vaccine containing a RNA molecule encoding an allergen or derivative thereof, in which the allergen is an allergen of Alnus glutinosa, Alternaria alternata, Ambrosia artemisiifolia, Apium graveolens, Arachis hypogaea, Betula verrucosa, Carpinus betulus, Castanea sativa, Cladosporium herbarum, Corylus avellana, Cryptomeria japonica, Cyprinus carpio, Daucus carota, Dermatophagoides pteronyssinus, Fagus sylvatica, Felis domesticus, Hevea brasiliensis, Juniperus ashei, Malus domestica, Quercus alba or Phleum pratense.

Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.

Abstract: A composition for facilitating localized delivery of energy and of therapeutic agents to a lesion in tissue is disclosed comprising nanoparticles of a polysaccharide, gelatin or a polymer, wherein the nanoparticles are complexed with tin ions. The composition may comprise one or more therapeutic agents. The composition may be configured to improve the thermal effect of RF energy on a lesion and or to release the therapeutic agents to the lesion when RF energy is applied.

Abstract: Stretchable, occlusive backing layers for transdermal drug delivery systems are disclosed, that maintain occlusivity after stretching. The backing layers are comprised of a stretchable backing material provided with an occlusive coating comprising a styrene-isoprene-styrene block copolymer and tackifier. Also described are transdermal drug delivery systems having such backing layers, including transdermal drug delivery systems for non-steroidal anti-inflammatory drugs (NSAIDs), and methods of making and using such backing layers and transdermal drug delivery systems.

Abstract: A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.